Wes Streeting pauses controversial puberty blockers trial over safety concerns

View coverage

“We sincerely hope that all organisations involved will heed the MHRA's warning and that the trial will ultimately be cancelled. The right way forward is clearly to focus instead on studying outcomes for the 2,000 young people who have already been given puberty blockers.”

Maya Forstater